1. Merk. Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate covid-19 in positive interim analysis of phase 3 study. Press release, 1 Oct 2021. https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
2. Medicines and Healthcare Products Regulatory Agency. Summary of product characteristics for Lagevrio. 2021. https://www.gov.uk/government/publications/regulatory-approval-of-lagevrio-molnupiravir/summary-of-product-characteristics-for-lagevrio#:~:text=Treatment%20with%20Lagevrio%20resulted%20in,hospitalised%20prior%20to%20their%20death
3. Food and Drug Administration. Coronavirus (covid-19) update: FDA authorizes additional oral antiviral for treatment of covid-19 in certain adults. Press release, 23 Dec 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain
4. Melillo G. How Biogen’s aduhelm approval marks a precipitous turning point for the FDA. 2021. https://www.ajmc.com/view/how-biogen-s-aduhelm-approval-marks-a-precipitous-turning-point-for-the-fda
5. Silverman E. FDA approves Sarepta’s controversial drug for Duchenne muscular dystrophy. 2016. https://www.statnews.com/pharmalot/2016/09/19/sarepta-wins-dmd-drug-approval/